A few words
About Us
History
H.O.P.E... Help Our Plight End
President, David Schultz – Co-Founder & Ryan’s Dad
Vice President, Maria Schultz – Co-Founder & Ryan’s Mom
Chairman of the Board, Jeannine Cimino – William Penn Bank
Vice-Chairman of the Board, Matthew Candelori – Kramer Beverage
Secretary, Andrea Meier – AAA Mid-Atlantic
Treasurer, Linda Ialacci – Linda Ialacci CPA, LLC
Board of Directors
Chris Cline – GEICO Hamilton
Justin Coecliff – Bank of America Merrill Lynch
Brian Klabbatz – Pennsylvania Steel Co., Inc.
Pat Locane – State of New Jersey
Kevin Manna – Jersey Mike’s
Joseph Vasta – JET Electric Testing, LLC
Nina Melker – William Penn Bank
Denise Powers – Citizens Bank
John Rossi – Colliers Engineering & Design, Inc
Bill Rue Jr. – Rue Insurance
Michael A. Sabo – Pulse Media,LLC
Andrew Sklarz – CURE Insurance Arena
Benny Tramo – Bloomberg LP
Cory Zeiter – Mixbin
Hope is all that we have since the day our son, Ryan, was diagnosed with Duchenne muscular dystrophy.
“Making the decision to have a child is momentous. It is to decide forever to have your heart go walking around outside your body.” ~ Elizabeth Stone
Never would we have thought that this could happen to our beautiful son. However, that is what most people say when facing such a devastating possibility that soon becomes an evident reality. When Ryan was diagnosed with DMD, we were forced to face our worst nightmare- that our child had a fatal disorder for which there is no treatment or cure. Although our dreams for Ryan’s lifelong future were stolen by this news, HOPE was left in its place.
“Life is not about waiting for the storm to pass… It’s about learning to dance in the rain” ~ Unknown
Hope is the inspiration for Ryan’s Quest. We founded this organization within two short months of learning of Ryan’s diagnosis. We endured many sleepless nights and days where the hurt and tears felt like they would never cease. Until suddenly, we became enlightened. We knew that crying wouldn’t save Ryan. We needed to fight this disease. We learned how to focus the intensity of our emotions into saving Ryan and other boys affected by Duchenne by increasing awareness and funding for DMD research through Ryan’s Quest.
“You can really change the world if you care enough” ~ Unknown
Funding for Duchenne Muscular Dystrophy has allowed scientists to take great strides toward better treatments and possibilities of finding a cure for this disease. Significant advances in molecular medicine and gene therapy have been made. Major biotech and pharmaceutical companies are now investing in research that will bring DMD therapies from the lab into our homes. Advocates are also working hard to gain the support of the federal government so that funds may be allocated on research for a cure. However, more funding is needed in order to further these efforts and to save these boys. Within the DMD community, experts agree that we are on the brink of a scientific breakthrough. “It is no longer a matter of IF…it is a matter of WHEN”. However, time is working against Ryan and these boys each day. We must act now to save their lives. DMD research has attained a promising team of doctors, scientists and families who are committed to this cause…we just need the resources to succeed in finding a cure!
“In a moment of decision, the best thing you can do is the right thing to do. The worst thing you can do is nothing.” ~ Theodore Roosevelt
Recent Funding
- $20,000 contribution to Michael’s Cause for the purpose of supporting an accessible vehicle for a Duchenne family (2022)
- $25,000 contribution to the Jett Foundation Giving Fund for the purpose of supporting The Accessible Vehicle Fund which helps families obtain safe, accessible transportation. (2022)
- $500 contribution towards World Duchenne Awareness Day through the Jett Foundation (2022)
- $31,000 contribution towards sponsoring the training and placement of a service dog for a child with Duchenne. (2022)
- $20,547 contribution towards the purchase of a handicapped accessible van and specialized wheelchairs for Duchenne children.(2021)
- $125,000 towards the development of the Duchenne Video Assessment (DVA) as a Novel Outcome Measure for Disease Progression and Patient Function in a Clinic, Post-Marketing, or Clinical Trial Setting. (2021)
- $25,000 contribution towards customized therapeutics for exon 45 deletions through Cure Rare Disease (2021)
- $10,000 contribution towards DMD motor function trajectories and outcome measures for clinical trial design and interpretation through MGH Institute for Health Professionals (2020)
- $25,000 contribution towards the Duchenne mapping project through Parent Project Muscular Dystrophy (2020)